Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Akoya Biosciences Inc (AKYA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: AKYA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -58.35% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 70.23M USD | Price to earnings Ratio - | 1Y Target Price 3.14 |
Price to earnings Ratio - | 1Y Target Price 3.14 | ||
Volume (30-day avg) 303312 | Beta 1.32 | 52 Weeks Range 1.32 - 4.65 | Updated Date 04/1/2025 |
52 Weeks Range 1.32 - 4.65 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-03 | When Before Market | Estimate -0.1625 | Actual -0.17 |
Profitability
Profit Margin -67.79% | Operating Margin (TTM) -26.84% |
Management Effectiveness
Return on Assets (TTM) -16.86% | Return on Equity (TTM) -180.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 119347063 | Price to Sales(TTM) 0.86 |
Enterprise Value 119347063 | Price to Sales(TTM) 0.86 | ||
Enterprise Value to Revenue 1.46 | Enterprise Value to EBITDA -6.83 | Shares Outstanding 49816400 | Shares Floating 15377811 |
Shares Outstanding 49816400 | Shares Floating 15377811 | ||
Percent Insiders 67.21 | Percent Institutions 69.85 |
Analyst Ratings
Rating 3.62 | Target Price 3.5 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Akoya Biosciences Inc
Company Overview
History and Background
Akoya Biosciences Inc. was founded in 2015, evolving from PerkinElmer's Phenoptics business. It focuses on spatial biology solutions for biomarker discovery and translational research. Significant milestones include the development of advanced imaging systems and reagents for multiplexed immunofluorescence.
Core Business Areas
- Instruments: Akoya develops and sells high-resolution imaging systems, primarily the PhenoImager HT and Fusion, which enable researchers to visualize and quantify multiple biomarkers within tissue samples.
- Reagents: Akoya offers a comprehensive portfolio of reagents, including antibodies, dyes, and kits, optimized for use with its imaging platforms.
- Services: Akoya provides contract research services, including assay development, image analysis, and data interpretation, supporting researchers in various applications.
Leadership and Structure
Brian McKelligon serves as CEO. The company is structured with functional departments covering R&D, Sales, Marketing, Operations, and Finance. There is also a board of directors providing governance.
Top Products and Market Share
Key Offerings
- PhenoImager HT: A high-throughput, automated imaging system for spatial phenotyping. No specific market share data publicly available. Competitors: Lunaphore, Canopy Biosciences (Bruker), Ultivue.
- PhenoCycler-Fusion System: A next-generation spatial biology platform with single-cell resolution. No specific market share data publicly available. Competitors: NanoString Technologies, 10x Genomics (Visium).
- CODEX: A technology for high-plex immunofluorescence imaging. No specific market share data publicly available. Competitors: NanoString Technologies (CosMx), Standard BioTools.
Market Dynamics
Industry Overview
The spatial biology market is rapidly growing, driven by increasing demand for insights into cellular interactions and disease mechanisms within intact tissues. Itu2019s fueled by oncology, immunology, and neuroscience research.
Positioning
Akoya is positioned as a leading provider of spatial biology solutions, offering a comprehensive portfolio of instruments, reagents, and services. Its competitive advantages include its advanced imaging capabilities and established customer base.
Total Addressable Market (TAM)
The TAM for spatial biology is estimated to reach billions of dollars in the coming years. Akoya aims to capture a significant share of this market with its integrated solutions.
Upturn SWOT Analysis
Strengths
- Advanced imaging technology
- Comprehensive portfolio of products and services
- Established customer base
- Strong brand recognition
- Experienced management team
Weaknesses
- High cost of instruments and reagents
- Complex data analysis workflows
- Limited marketing presence compared to larger competitors
- Reliance on capital equipment sales
Opportunities
- Expanding into new application areas (e.g., drug discovery, diagnostics)
- Developing cloud-based data analysis solutions
- Partnering with pharmaceutical companies
- Increasing market penetration in emerging markets
Threats
- Competition from larger, well-funded companies
- Technological advancements that could render existing products obsolete
- Economic downturns that could reduce research funding
- Regulatory changes that could impact the market
Competitors and Market Share
Key Competitors
- NVST
- TXG
- STB
Competitive Landscape
Akoya offers a niche, high-end product, balancing resolution and throughput with CODEX, while also offering high throughput options. Competition is strong, from niche and large players.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by increased adoption of spatial biology technologies.
Future Projections: Analysts expect continued growth driven by product innovation and market expansion.
Recent Initiatives: Recent initiatives include the launch of new products and partnerships with pharmaceutical companies.
Summary
Akoya Biosciences is a key player in the growing spatial biology market with innovative products, but faces competition from larger companies and requires continued investment in R&D. Its strengths lie in its advanced technology and established customer base. Potential weaknesses include high costs and complex data workflows, while opportunities exist in expanding into new applications and developing cloud-based solutions. Akoya needs to be wary of competition and economic downturns.
Similar Companies
- NVST
- TXG
- STB
Sources and Disclaimers
Data Sources:
- Akoya Biosciences Inc. Investor Relations
- Analyst Reports
- Company Filings
- Spatial Biology Industry Reports
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It should not be considered financial advice. Market share data is approximate and may vary. Please consult with a qualified professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akoya Biosciences Inc
Exchange NASDAQ | Headquaters Marlborough, MA, United States | ||
IPO Launch date 2021-04-16 | President, CEO & Director Mr. Brian McKelligon | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 205 | Website https://www.akoyabio.com |
Full time employees 205 | Website https://www.akoyabio.com | ||
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. Akoya Biosciences, Inc. was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.